Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective.

Tanner, Julie-Anne; Davies, Paige E; Overall, Christopher C; Grima, Daniel; Nam, Julian; Dechairo, Bryan M

Tanner, Julie-Anne; Davies, Paige E; Overall, Christopher C; Grima, Daniel; Nam, Julian; Dechairo, Bryan M.

Affiliation

Tanner JA; Assurex Health Ltd, a subsidiary of Myriad Neuroscience, Toronto, ON, M5T 1L8, Canada.
Davies PE; Assurex Health Ltd, a subsidiary of Myriad Neuroscience, Toronto, ON, M5T 1L8, Canada.
Overall CC; Myriad Genetics Inc., Salt Lake City, UT 84108, USA.
Grima D; Cornerstone Research Group Inc., Burlington, ON, L7N 3H8, Canada.
Nam J; Hoffmann-La Roche Ltd, Mississauga, ON, L5N 5M8, Canada.
Dechairo BM; Myriad Genetics Inc., Salt Lake City, UT 84108, USA.

Pharmacogenomics ; 21(8): 521-531, 2020 06.

Article in En | MEDLINE | ID: mdl-32301648

Subject(s)

Cost-Benefit Analysis/methods; Depression/economics; Depression/epidemiology; National Health Programs/economics; Pharmacogenomic Testing/economics; Pharmacogenomic Testing/methods; Canada/epidemiology; Depression/diagnosis; Humans

Key words

ICER; QALY; cost; cost saving; costeffectiveness; depression; genetic testing; pharmacogenetics; pharmacogenomics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cost-Benefit Analysis / Depression / Pharmacogenomic Testing / National Health Programs Type of study: Diagnostic_studies / Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Country/Region as subject: America do norte Language: En Journal: Pharmacogenomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2020 Document type: Article Affiliation country: Canada Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google